Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Pastocovac and Pastocovac Plus As Protein Subunit Covid-19 Vaccines Led to Great Humoral Immune Responses in Bbip-Corv Immunized Individuals Publisher Pubmed



Ramezani A1 ; Sorouri R2 ; Haji Maghsoudi S3, 4 ; Dahmardeh S5 ; Doroud D6 ; Sadat Larijani M1 ; Eybpoosh S7 ; Mostafavi E7 ; Olyaeemanesh A8 ; Salehivaziri M9 ; Bavand A1 ; Zarghani G5 ; Moradi L1 ; Ashrafian F1 Show All Authors
Authors
  1. Ramezani A1
  2. Sorouri R2
  3. Haji Maghsoudi S3, 4
  4. Dahmardeh S5
  5. Doroud D6
  6. Sadat Larijani M1
  7. Eybpoosh S7
  8. Mostafavi E7
  9. Olyaeemanesh A8
  10. Salehivaziri M9
  11. Bavand A1
  12. Zarghani G5
  13. Moradi L1
  14. Ashrafian F1
  15. Bagheri Amiri F7
  16. Mashayekhi P10
  17. Tahmasebi Z7
  18. Biglari A11
Show Affiliations
Authors Affiliations
  1. 1. Clinical Research Department, Pasteur Institute of Iran, No 69, Pasteur Ave., Tehran, Iran
  2. 2. IPI Directorate, Pasteur Institute of Iran, Tehran, Iran
  3. 3. Modeling in Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
  4. 4. Department of Biostatistics and Epidemiology, School of Public Health, Kerman University of Medical Sciences, Kerman, Iran
  5. 5. Department of Vaccination, Pasteur Institute of Iran, Tehran, Iran
  6. 6. Quality Control Department, Production and Research Complex, Pasteur Institute of Iran, Tehran, Iran
  7. 7. Department of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran
  8. 8. Health Equity Research Centre and National Institute of Health Research, Tehran University of Medical Science, Tehran, Iran
  9. 9. COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran
  10. 10. Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
  11. 11. School of Medicine, Tehran University of Medical Sciences, Enghelab Street, P.O. BOX 14155-6559, Tehran, Iran

Source: Scientific Reports Published:2023


Abstract

The optimal booster vaccine schedule against COVID-19 is still being explored. The present study aimed at assessment of the immunogenicity and antibody persistency of inactivated-virus based vaccine, BBIP-CorV and protein-subunit based vaccines, PastoCovac/Plus through heterologous and homologous prime-boost vaccination. Totally, 214 individuals who were previously primed with BBIBP-CorV vaccines were divided into three arms on their choice as heterologous regimens BBIBP-CorV/PastoCovac (n = 68), BBIBP-CorV/PastoCovac Plus (n = 72) and homologous BBIBP-CorV (n = 74). PastoCovac booster recipients achieved the highest rate of anti-Spike IgG titer rise with a fourfold rise in 50% of the group. Anti-RBD IgG and neutralizing antibody mean rise and fold rise were almost similar between the PastoCovac and PastoCovac Plus booster receivers. The antibody durability results indicated that the generated antibodies were persistent until day 180 in all three groups. Nevertheless, a higher rate of antibody titer was seen in the heterologous regimen compared to BBIP-CorV group. Furthermore, no serious adverse event was recorded. The protein subunit-based booster led to a stronger humoral immune response in comparison with the BBIP-CorV booster receivers. Both the protein subunit boosters neutralized SARS-CoV-2 significantly more than BBIP-CorV. Notably, PastoCovac protein subunit-based vaccine could be successfully applied as a booster with convenient immunogenicity and safety profile. © 2023, The Author(s).
Related Docs
1. Immunogenicity and Safety of Heterologous Boost Immunization With Pastocovac Plus Against Covid-19 in Chadox1-S or Bbibp-Corv Primed Individuals, PLoS Pathogens (2023)
2. Evaluation of Pastocovac Plus Vaccine As a Booster Dose on Vaccinated Individuals With Inactivated Covid-19 Vaccine, Heliyon (2023)
3. Efficacy and Safety of an Inactivated Virus-Particle Vaccine for Sars-Cov-2, Biv1-Coviran: Randomised, Placebo Controlled, Double Blind, Multicentre, Phase 3 Clinical Trial, BMJ (2023)
4. Safety and Immunogenicity of Corenapcin, a Sars-Cov-2 Mrna Vaccine, As a Fourth Heterologous Booster in Healthy Iranian Adults: A Double-Blind, Randomized, Placebo-Controlled, Phase 1 Clinical Trial With a Six-Month Follow-Up, International Immunopharmacology (2024)
5. Efficacy and Safety of a Protein-Based Sars-Cov-2 Vaccine: A Randomized Clinical Trial, JAMA Network Open (2023)
6. The Impact of Abo Blood Types on Humoral Immunity Responses and Antibody Persistency After Different Covid-19 Vaccine Regimens, Journal of Medical Virology (2024)
Experts (# of related papers)
View all Related Experts
Alireza Biglari (3)
Mohammadreza Salehi (2)